Clinical Trials

Searchable database of currently enrolling clinical trials

Androgen Receptor Addiction in Prostate Cancer, Breaking the Habit

Evan Y. Yu
March 01, 2023

Androgen receptor (AR) signaling is the most important driver of prostate cancer initiation, development, and progression, even into the castration-resistant state.  Androgen deprivation therapy (ADT) is the original “targeted therapy” in oncology.  The next generation androgen- and AR-targeted agents, such as abiraterone acetate, enzalutamide, apalutamide and darolutamide further prove the concept that AR signaling remains critical in even later disease states.  There are various mechanisms of resistance that continue to be inclusive of AR; this ranges from AR amplification, AR mutation, and potentially AR spliced variants.


Dr. Evan Yu, MD

Evan Y. Yu, MD

Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biological mechanisms of drug sensitivity and resistance.

Clinical Expertise

Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.

  • Section Head, Cancer Medicine, Clinical Research Division Fred Hutchinson Cancer Center
  • Medical Director, Clinical Research Support Fred Hutchinson Cancer Research Consortium
  • Professor of Medicine Division of Oncology, Department of Medicine University of Washington School of Medicine Seattle, WA
Search Clinical Trials by Disease

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.